

## PERSONAL INFORMATION

Ana Clara

## WORK EXPERIENCE

November 2013–Present

**Medical Oncologist**

Instituto Português de Oncologia Francisco Gentil, EPE, Lisboa (Portugal)

Assessment, diagnosis and treatment of oncological patients

Assistance in internment, consultations, Multidisciplinary therapeutic decision groups,

November 2016–Present

**Clinical evaluator**

INFARMED - National Authority of Medicines and Health Products, IP (Portugal)

Member of CAM (comissão de avaliação de medicamentos - November 2016) e CATS (Comissão de Avaliação de Tecnologias da Saúde - February 2017)

## EDUCATION AND TRAINING

February 2008–October 2013

**Medical Oncology Internship**

Instituto Português de Oncologia Francisco Gentil EPE, Lisboa (Portugal)

Internal Medicine, Intensive Care Unit, Infectious Diseases, Medical Oncology, Hematology and Bone Marrow Transplantation, Radiotherapy, Pneumology, Neuro-Oncology

February 2007–February 2008

**General Internship resident**

Centro Hospitalar Lisboa Central - Hospital de São José (Portugal)

October 2009–August 2010

**Post Graduation Course in Palliative Care**

Instituto Ciências da Saúde da Universidade Católica Portuguesa, Lisboa (Portugal)

2000–2006

**Degree in medicine**

Universidade Nova de Lisboa - Faculdade de Ciências Médicas (Portugal)

## ADDITIONAL INFORMATION

**Expertise**

- Gastrointestinal cancer
- Member of Multidisciplinary therapeutic decision groups - gastrointestinal cancer.
- Hereditary breast and ovarian cancer syndrom

**Publications**

" Unexpected long-term survival in a BRCA 2 patient with metastatic carcinosarcoma associated with tamoxifen" - Ana Clara, Isabel Fonseca, Ana Francisca, António Bettencourt and Fátima Vaz. *Serviços de Oncologia Médica, Anatomia Patológica, Ginecologia, Cirurgia Geral. Gynecologic Oncology Case Reports* 4:44-46, January 2013.

Poster presentations in International Conferences, as first autor:

1) "Micro RNA expression in BRCA1/2 hereditary breast cancer: exploratory analysis."

Ana Clara, Patrícia Machado, Ana Luíís, Ana Opinião, Carla Simões, Joana Parreira, Paula Rodrigues, Susana Esteves, Fátima Vaz. ESMO congress, Amsterdam, 2013.

2) "Autologous Stem Cell Transplantation for high-risk Ewing's Sarcoma: a single center review" Ana Clara, Filipa Moita, Isabelina Ferreira, Gilda Teixeira, Nuno Miranda, F. Leal da Costa, M Abecassis. Departments of Medical Oncology, Pediatrics and bone marrow transplantation. Geneve EBMT 2012

3) "Perioperative chemotherapy in resectable gastric cancer- a single center review" Ana Clara, Teresa Alexandre, Ana Luíís, João Freire, João Oliveira. Medical Oncology IPOLFG, Stockholm

## ESMO 2011

4) " Follow-up of BRCA 1/2 carriers: the spectrum of cancer diagnoses in healthy at risk individuals (HTR) and in cancer survivors (CS)". Ana Clara, Carlos Santos Costa, Jorge Silva, José Carlos Marques, Cecília Moura, Saudade André, Ana Luís, Sandra Bento, Ana Opinião, Paula Rodrigues, Patrícia Machado, Sofia Fragoso, Sidónia Santos and Fátima Vaz. Departments of Medical Oncology, General Surgery, radiology, Urology, Dermatology, Pathology, Breast Cancer Risk Evaluation Clinic of IPOLFG, San António 2011

5) "Review of breast cancer diagnosed in a cohort of BRCA1/2 carriers." Ana Clar, Carlos Santos Costa, José Carlos Marques, Ana Luís, Ana Opinião, Sandra Bento, Paula Rodrigues, Saudade André, João Oliveira, Fátima Vaz. Medical Oncology, Breast Surgery, Radiology, Breast Cancer Evaluation Clinic, Pathology, IPOLFG, St Gallen Breast Cancer Conference 2011.

## Projects

1) Basic Research 2013 - Principal investigator in the research project "miRNA expression characterization in a population with hereditary breast-ovarian cancer, with BRCA 1/2 mutation."

2) Clinical Research -.Principal investigator at IPOLFG EPE of study "Prognóstico de cancro da mama associado à mutação fundadora portuguesa no gene BRCA2 C. 156\_157insAlu". Sponsor - ASPIC Associação Portuguesa de Investigação em Cancro (Academic); Since 2019

3) Participation in clinical trials as investigator:

- LUME OVAR - multicentre, randomized, double-blind, phase III trial to investigate the efficacy and safety of study drug in combination with standard (first-line) treatment of carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer.

- AURELIA - avastin use in platinum-resistant epithelial ovarian cancer - a multi-centre, open-label, randomised, two-arm phase 3 trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer.

- LUX-Breast 1 - An open label, randomised phase III trial of BIBW 2992 and vinorelbine in patients with metastatic Her2-overexpressing breast cancer failing one prior trastuzumab treatment.

- A PHASE III, double-blind, randomized parallel-group active-controlled study to compare the efficacy and safety of CT-P& and Herceptin as neoadjuvant treatment in patients with Her2-positive early breast cancer. [CT-P6-3.2]

- A phase 3 randomized open-label study of single agent pembrolizumab vs physicians' choice of single agent docetaxel, paclitaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma and squamous cell carcinoma of the esophagus that have progressed after first-line standard therapy

- A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy - OLYMPIA Study

4) Participation as a speaker in the following training courses for doctors and other professionals:

- "Chemoprophylaxis and systemic treatment in pre invasive breast lesions: yes or no?" - Encontros da Primavera, topic Breast Cancer, Évora, 2014.

- "Referencing criteria: who to study and with which methodology?" - IX Congresso de Senologia - Hereditary Breast Cancer, Cascais, Outubro 2015.

- "Colorectal cancer: clinical cases presentation and discussion" XIII Curso de Oncologia Clínica, IPOLFG, Lisboa, November 2015.

- "Breast Cancer Evaluation Clinic - who is followed up?" - formation for pharmaceutical industry members, IPOLFG, January 2016, Lisboa.

5) Participation in organization of the conference "Familial Risk Conference" promoted by Liga Portuguesa Contra o Cancro, Lisboa, Setembro de 2017.

## Memberships

1) Ordem dos Médicos. Licence number nº 46070, Secção Regional do Sul

2) European Society for Medical Oncology (ESMO) - May 2012

## Other Relevant Information

1) Mentor of two resident doctors of Medical Oncology, Instituto Português de Oncologia de Lisboa, Francisco Gentil, EPE; Lisboa

2) Training in Good Clinical Practice (2020)